Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Editor
New York, USA
24+ years of experience
Scrip
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Scrip
By Jessica Merrill 14 Nov 2022
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Scrip
By Jessica Merrill 19 Oct 2021
The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.
Scrip
By Jessica Merrill 04 May 2021
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.
Scrip
By Jessica Merrill 20 Apr 2021
J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.
Scrip
By Jessica Merrill 27 Nov 2020
The company – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.
Topic Coronavirus Vaccines
Scrip
By Jessica Merrill 27 Nov 2020
Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.
Topic BioPharmaceutical
Scrip
By Jessica Merrill 17 Nov 2020
Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.
Scrip
By Jessica Merrill 19 Oct 2020
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.
Scrip
By Jessica Merrill 01 Jun 2020
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.
Topic Coronavirus
Scrip
By Jessica Merrill 30 Apr 2020
A Phase III trial testing Kevzara in hospitalized COVID-19 patients will continue only with the high dose in more advanced critical patients after the low-dose was unsuccessful.
Scrip
By Jessica Merrill 19 Mar 2020
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.
Topic Coronavirus
Scrip
By Jessica Merrill 12 Mar 2020
Amid a stock market freefall spurred largely by coronavirus uncertainty, big pharma sought to reassure investors and the public that supply disruptions are not an immediate concern and they are monitoring business operations day-by-day.
Topic Coronavirus
Scrip
By Jessica Merrill 08 Jan 2020
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
Topic Deals Leadership M A
Scrip
By Jessica Merrill 28 Nov 2019
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
Medtech Insight
22 Jul 2022
Medtech Insight
22 Jul 2022
Scrip
21 Jul 2022
Scrip
21 Jul 2022
Scrip
19 Jul 2022
Scrip
18 Jul 2022
Scrip
15 Jul 2022
Scrip
13 Jul 2022
Scrip
12 Jul 2022
Scrip
11 Jul 2022
Scrip
07 Jul 2022
Scrip
06 Jul 2022
Scrip
05 Jul 2022
Scrip
04 Jul 2022
Scrip
23 Jun 2022
